Therefore, cohort studies that continuously monitor CD4+ T cells levels or control studies that clearly distinguish patients with early or advanced HCC are needed to study the high/low CD4 expression levels at different stages of HCC. This evidence concerns the gene CD4 and hepatocellular carcinoma.